Biogen has partnered with BioMotiv to identify neuroscience discoveries and translate them into new drugs, under a collaboration that will generate $15 million over five years for the biotech accelerator.
In return, Biogen will receive exclusive rights relating to neuroscience programs sourced and developed by BioMotiv, which announced the partnership today.
“Biogen is committed to working with the world's leading clinicians and scientists to accelerate the discovery of novel neuroscience medicines,” Spyros Artavanis-Tsakonas, svp and CSO at Biogen, said in a statement.
The announcement did not specify which areas of neurology the partners would focus on. Neurological disorders represent one of three therapeutic areas of focus for Biogen, along with autoimmune and hematologic disorders.
Launched in 2012, BioMotiv is the for-profit accelerator of The Harrington Project for Discovery & Development, a $250 million effort focused on commercializing drugs developed by physician scientists. The project is centered at Cleveland’s University Hospitals, and also includes the not-for-profit Harrington Discovery Institute.
Last year BioMotiv launched a $25 million partnership with Takeda Pharmaceutical to identify and develop new therapeutics “specifically in the therapeutic areas of immunology & inflammation, and cardio-metabolic diseases.”